Company news

Entera Bio Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session

October 5, 2021

Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting

August 31, 2021

Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference

August 22, 2021

Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021

August 22, 2021

Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates

August 15, 2021

Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021

August 12, 2021

Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

August 1, 2021

Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis

June 27, 2021

Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints

June 22, 2021

Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union

June 16, 2021

Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates

May 19, 2021

Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors

April 19, 2021

Entera Appoints Ramesh Ratan as Chief Financial Officer

April 14, 2021

New Data Suggest Entera’s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress

April 5, 2021

Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020

March 17, 2021

Entera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021

March 10, 2021

Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data

March 10, 2021

Entera Bio To Present At The H.C. Wainwright Global Life Sciences Conference

March 3, 2021

Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research

February 24, 2021

Entera Bio Initiates New Research Program For Oral GLP-2

February 7, 2021

Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis

December 9, 2020

Entera Bio Appoints Spiros Jamas as Chief Executive Officer

November 29, 2020

Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update

November 18, 2020

Entera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020

November 12, 2020

Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis

November 8, 2020

Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results

August 19, 2020

Entera Bio to Report Second Quarter 2020 Business and Financial Results on August 20, 2020

August 16, 2020

Entera Bio Announces Management Changes

August 9, 2020

Entera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results

July 21, 2020

Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis

July 6, 2020

Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results

May 20, 2020

Entera Bio to Report Interim Data From EB613 Phase 2 Trial and First Quarter 2020 Business and Financial Results on May 21, 2020

May 6, 2020

Entera Bio Ltd announces financial and operating results for the fourth quarter and Year Ended December 31, 2019

March 25, 2020

Entera Bio to report 2019 business and financial results on March 26, 2020

March 15, 2020

Entera Bio Announces the Completion of $14.3 million Private Placement

December 17, 2019

Entera Announces Closing of Private Placement

December 10, 2019

Entera Bio Reports Third Quarter 2019 Financial Results and Provides Operating Update

November 20, 2019

Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer

November 20, 2019

Entera Bio to Announce Third Quarter 2019 Financial Results on Thursday, November 21, 2019

November 6, 2019

Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism

September 22, 2019

← Newer news releases

Calls

Decks

The 5 newest of 9 decks. Every deck is listed under its year.